Pulmonary Embolism

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial – Fingerprint — University of Edinburgh Research Explorer Sort by Weight Alphabetically Medicine & Life Sciences Rivaroxaban 100% Aortic Diseases 94% Warfarin 80% Mitral Valve 76% Aortic […]

Introduction: Sickle cell disease (SCD) is a hematological disorder characterized by sickling of red blood cells. Patients are at increased risk of venous thromboembolism. There are no guidelines for the management of venous thromboembolism in sickle cell disease specifically in terms of the anticoagulant of choice. Patient concerns: Here, we report a case of a […]

Primary outcomes included all-cause hospitalization, stroke and major bleeding, stroke and systemic embolism. Overall, the authors found that the adjusted hazard ratio from the meta-regression analyses was 0.88 to 0.95, indicating a significantly lower hazard of stroke/systemic embolism associated with apixaban compared with rivaroxaban. The authors also found that pair-wise meta-analyses showed that the pooled […]

This article was originally published here Am J Cardiovasc Drugs. 2021 Dec 20. doi: 10.1007/s40256-021-00514-5. Online ahead of print. ABSTRACT BACKGROUND: The choice of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) is at the physician’s discretion; however, it is useful to know the differences in the clinical data of DOACs to help physicians choose. […]

Hematologic Flashcards | Quizlet   heparinwarfarin Factor Xa inhibitors -Myocardial infarction-ischemic stroke-DVT/PE-atrial fibrillation -after surgery-extended immobilization -treat DVT-MOA: increase antithrombin activity which binds and inactivates clotting factors (thrombin, IXa, Xa)-IV or injection: rapid onset -MUST monitor INR, partial thromboplastin, and platelets -side effects: bleeding (thrombocytopenia) -treat long term prevention of DVT and treat a-fib-MOA: interferes […]

Quick Takes More than 36,000 patients with VTE newly starting apixaban or rivaroxaban were compared and followed for >3 months using medical claims. Use of apixaban was associated with a lower risk of intracranial or gastrointestinal bleeding as compared to rivaroxaban therapy. Use of apixaban was associated with a lower risk of recurrent VTE as […]

Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Medication Pearl of the Day: Dabigatran Etexilate (Pradaxa) Indication: Dabigatran etexilatecapsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in […]

False Question 2 0 out of 10 points Please use the nomogram… Image transcription text False Question 2 0 out of 10 points Please use the nomogram provided in the Anticoagulants PPT for reference. You patient is on a heparin infusion for treatment of a pulmonary embolism. Pt weight 220 pounds. Your patient is currently […]

This article was originally published here Res Pract Thromb Haemost. 2021 Nov 30;5(8):e12604. doi: 10.1002/rth2.12604. eCollection 2021 Dec. ABSTRACT BACKGROUND: Patients with cancer-associated thrombosis (CAT) have a high risk of recurrent venous thromboembolic events, which contribute to significant morbidity and mortality. Direct oral anticoagulants may provide a convenient treatment option for these patients. OBJECTIVES: To […]

Patients with venous thromboembolism (VTE) who received apixaban had a lower rate of recurrence, as well as intracranial and gastrointestinal bleeding events, compared with those treated with rivaroxaban, a recent study found. The retrospective new-user cohort study used a U.S.-based commercial health care insurance database to compare outcomes between patients with VTE who were newly […]

Background: Apixaban and rivaroxaban are replacing vitamin K antagonists for the treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons remain limited. Objective: To assess the effectiveness and safety of apixaban compared with rivaroxaban in patients with VTE. Design: Retrospective new-user cohort study. Setting: U.S.-based commercial health care insurance database from 1 January 2015 […]

The tentatively approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Pradaxa Dabigatran Etexilate Mesylate capsules, Eq to 150 mg base, Boehringer Ingelheim Read Article Alembic Pharmaceuticals yesterday announced that it has received tentative approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dabigatran […]

Anticoagulation is widely used in the inpatient setting for various indications for both surgical and medical patients including stroke prevention in non-valvular atrial fibrillation, prevention of venous thromboembolism in post-surgical patients, management of acute coronary syndromes, and treatment of acute thrombosis. For patients with acute thrombosis, anticoagulation is the key therapy to stabilize the thrombus, […]

Factor eight inhibitor bypassing activity (aPCC) is recommended as a non-specific reversal agent for direct oral anticoagulants (DOACs) according to the 2017 American College of Cardiology (ACC) guidelines for reversal of anticoagulation. Factor eight inhibitor bypassing activity carries a black box warning for thrombotic events such as stroke, pulmonary embolism, deep vein thrombosis, and myocardial […]

Although there is no age criterion for rivaroxaban dose reduction, elderly patients with atrial fibrillation (AF) are often prescribed an off-label reduced dose. We aimed to evaluate whether age is a necessary criterion for rivaroxaban dose reduction in Korean patients with AF. Among 2208 patients who prescribed warfarin or rivaroxaban, 552 patients over 75 years […]

Heparin  MOA: binds irreversibly to the endogenous antithrombin III through a key pentasaccride accelerating the action of antithrombin III by 1000 folds leading to increased inactivation of factor X and factor III  Clinical uses o Quick reversal of thrombosis o Venous thrombosis o Pulmonary embolism o Acute coronary syndromes  Limiations o Bind […]

Background Thromboprophylaxis extended after hospital discharge in medically ill patients currently is not recommended by practice guidelines because of uncertainty about the benefit for preventing major or fatal thromboembolic events, and the risk of bleeding. Methods and Results We assessed the benefit and risk of thromboprophylaxis with rivaroxaban 10 mg once daily extended for 25 […]

Rivaroxaban (Xarelto; Janssen) found superior to aspirin in reducing the risk of recurrent stroke or systemic embolism in patients with left ventricular dysfunction. Data from the phase 3 NAVIGATE ESUS trial indicate that rivaroxaban (Xarelto; Janssen) is superior to aspirin in decreasing the risk of recurrent stroke or systemic embolism in patients with left ventricular […]

Week 6 Pre-lab Assignment Directions: Along with answering each question below, provide a supporting rationale for it. The responses must be sourced with an appropriate reference in proper APA format. 1. The doctor has prescribed heparin for your patient, which belongs to what specific category/class of medications? Why (based on its action)?  Anticoagulant. Binding […]

Post-hoc analysis from the phase 3 NAVIGATE ESUS trial (NCT02313909) provided evidence that rivaroxaban (Xarelto; Janssen), an anticoagulant, was superior to aspirin at reducing the risk of recurrent stroke or systemic embolism in patients with left ventricular (LV) dysfunction. Led by Alexander E. Merkler, MD, MS, assistant professor of neurology, Weill Cornell Medicine, the study […]